High-dose nevirapine: Safety, pharmacokinetics, and antiviral effect in patients with human immunodeficiency virus infection

Journal of Infectious Diseases

Volumn 171, Issue 3, 1995, Pages 537-545

  Havlir, Diane ^a,b,c,d   Cheeseman, Sarah H ^a,b,c,d   Mc Laughlin, Margaret ^a,b,c,d   Murphy, Robert ^a,b,c,d   Erice, Alejo ^a,b,c,d   Spector, Stephen A ^a,b,c,d   Greenough, Thomas C ^a,b,c,d   Sullivan, John L ^a,b,c,d   Hall, David ^a,b,c,d   Myers, Maureen ^a,b,c,d   Lamson, Michael ^a,b,c,d   Richman, Douglas D ^a,b,c,d  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF MASSACHUSETTS   (United States)

^c BOEHRINGER INGELHEIM PHARMACEUTICALS INC   (United States)

^d NORTHWESTERN UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIGEN P24; DIDANOSINE; NEVIRAPINE; RNA DIRECTED DNA POLYMERASE INHIBITOR; VIRUS RNA; ZALCITABINE; ZIDOVUDINE;

ADULT; ANTIGEN ANTIBODY COMPLEX; ANTIVIRAL ACTIVITY; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; DRUG BLOOD LEVEL; DRUG ERUPTION; DRUG MEGADOSE; DRUG RESISTANCE; DRUG SAFETY; FEVER; HEADACHE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MALE; ORAL DRUG ADMINISTRATION; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL;

ADULT; ANTIVIRAL AGENTS; HIV CORE PROTEIN P24; HIV INFECTIONS; HUMAN; MIDDLE AGE; NEVIRAPINE; PYRIDINES; REVERSE TRANSCRIPTASE INHIBITORS; RNA, VIRAL; SUPPORT, NON-U.S. GOV'T; SUPPORT, U.S. GOV'T, NON-P.H.S.; SUPPORT, U.S. GOV'T, P.H.S.;

EID: 0028930117     PISSN: 00221899     EISSN: 15376613     Source Type: Journal    
DOI: 10.1093/infdis/171.3.537     Document Type: Article

References (26)

1. De Ciercq E. HIV inhibitors targeted at the reverse transcriptase. AIDS Res Hum Retroviruses 1992;8:1 19-34
2. Volberding PA, Lagakos SW, Koch MA. et al. Zidovudine in asymptomatic human immunodeficiency virus infection. A controlled trial in persons with fewer than 500 CD4-positive cells per cubic millimeter. The AIDS Clinical Trials Group of the National Institute of Allergy and Infectious Disease. N Engl J Med 1990;322:941-9
3. Fischl MA, Richman DD, Greico MH. et al. The efficacy of azidothy-midine (AZT) in the treatment of patients with AIDS and AIDS-refated complex. N Engl J Med I987;317:185-91
4. Kahn JO. Lagakos SW, Richman DD, et al. A controlled trial comparing continued zidovudine with didanosine in human immunodeficiency virus infection. N Engl J Med 1992;327:581-7
5. Cohen KA, Hopkins J, Ingraham RH, et al. Characterization of the binding site for nevirapine (BI-RG-587), a non-nucleoside inhibitor of human immunodeficiency virus type-1 reverse transcriptase. J Biol Chem 1991;266:14670-4
6. Condra JH. Emini EA, Gotlib L, et al. Identification of the human immunodeficiency virus reverse transcriptase residues that contribute to the activity of diverse nonnucleoside inhibitors. Antimicrob Agents Chemother 1992;36:1441-6
7. Shih CK. Rose JM, Hansen GL. Wu JC, Bacolla A. Griffin JA. Chimeric human immunodeficiency virus type 1/type 2 reverse transcriptase display reversed sensitivity to nonnucleoside analog inhibitors. Proc Natl Acad Sci USA 1991;88:9878-82
8. Richman DD, Rosenthal AS. Skoog M, Eckner RJ, Sabo JP, Merluzzi VJ. BI-RG-587 is active against zidovudine-resistant human immunodeficiency virus type I and synergizes with zidovudine. Antimicrob Agents Chemother 1991;35:305-8
9. Merluzzi VJ. Hargrave KD. Labadia M. et al. Inhibition of HIV-1 replication by a nonnucleoside reverse transcriptase inhibitor. Science 1990;250:141 1-3
10. Koup RA, Merluzzi VJ. Hargrave KD. et al. Inhibition ofhuman immunodeficiency virus type 1 (HIV-1) replication by the dipyridodiaze-pinone BI-RG-587. J Infect Dis 1991;163:966-70
11. Cheeseman SH. Hattox SE. McLaughlin MM. et al. Pharmacokinetics of nevirapine: initial single-rising-dose study in humans. Antimicrob Agents Chemother 1993;37:178-82
12. Richman DD. Shih CK, Lowy I, et al. Human immunodeficiency virus type 1 mutants resistant to nonnucleoside inhibitors of reverse transcriptase arise in tissue culture. Proc Natl Acad Sci 1991;88:11241 — 5
13. Cheeseman SH, Havlir D, McLaughlin M. et al. Phase 1/11 evaluation of nevirapine alone and in combination with zidovudine for infection with human immunodeficiency virus. J Acquir Immune Defic Syndr 1994 (in press)
14. Richman DD, Havlir D. Corbeil J. et al. Nevirapine resistance mutations of human immunodeficiency virus type 1 selected during therapy. J Virol 1994;68:1660-6
15. Richman DD, Johnson VA, Mayers DL, Shirasaka T, O'Brien MC, Mitsuya H. In vitro evaluation of experimental agents for anti-HIV activity. In: Coligan JE. Kruisbeck AM, Margulies DH, Sheyach EM, Stober W, eds. Current protocols in immunology. New York: John Wiley. 1993
16. Jayaraj A. Alexander J. Price C. A rapid and sensitive HPLC-UV method for the quantitation of an anti-HIV agent, nevirapine and its solid-phase extractable metabolites in biological fluids. Pharm Res 1992;9:S334
17. Gibaldi M. Pharmacokinetics. New York: Marcel Dekker, 1982
18. Bacolla A. Shih CK., Rose JM. el al. Amino acid substitutions in H1V-I reverse transcriptase with corresponding residues from HIV-2: effect on kinetic constants and inhibition by nonnucleoside analogs. J Biol Chem 1993;268:16571-7
19. Saag MS, Emini EA. Laskin OL. et al. A short-term clinical evaluation of L-697.661, a non-nucleoside inhibitor ofHIV-1 reverse transcriptase. N Engl J Med 1993;329:1065-72
20. Nunberg JH, Schleif WA, Boots EJ, et al. Viral resistance to human immunodeficiency virus type I -specific pyridinone reverse transcriptase inhibitors. J Virol 1991;65:4887-92
21. Richman DD. Resistance to clinical isolates to HIV to antiretroviral agents. Antimicrob Agents Chemother 1993;37:1207-13
22. Havlir D, Murphy R. Saag M. Kaul I. Johnson V, Richman DD. Nevirapine: further dose escalation of monotherapy (600 mg/daily) and combination therapy with zidovudine [abstract 268], In: Program and abstracts: First National Conference on Human Retroviruses and Related Infections (Washington, DC), 1993
23. Cheeseman SH, Murphy RL, Saag MS, Havlir D. Safety of high dose nevirapine (NVP) after 200 mg/d lead-in [abstract 262109], In: Program and abstracts: IX International Conference on AIDS/IV STD World Congress (Berlin). London: Wellcome Foundation. 1993
24. Saag MS, Sommadossi JP, Rainey D, et al. Pharmacokinetics and antiretroviral activity study of nevirapine in combination with zidovudine plus zalcitabine, zidovudine plus didanosine. or didanosine alone [abstract 270]. In: Program and abstracts: First National Conference on Human Retroviruses and Related Infections (Washington, DC), 1993
25. Chow YK, Hirsch MS, Merill DP, et al. Use of evolutionary limitations of HIV-1 multidrug resistance to optimize therapy. Nature 1993;361:650-4
26. Otto MJ, Garber S, Winslow DL. et al. In vitro isolation and identification of human immunodeficiency virus (HIV) variants with reduced sensitivity to C-2 symmetrical inhibitors of HIV type 1 protease. Proc Natl Acad Sci USA 1993;60:7543-7